Capper, D., Deimling, A. v., & Wick, W. (2017). Biomarker and histopathology evaluation of patients with recurrent glioblastoma treated with galunisertib, lomustine, or the combination of galunisertib and lomustine. International journal of molecular sciences, 18(5), . https://doi.org/10.3390/ijms18050995
Chicago-Zitierstil (17. Ausg.)Capper, David, Andreas von Deimling, und Wolfgang Wick. "Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine." International Journal of Molecular Sciences 18, no. 5 (2017). https://doi.org/10.3390/ijms18050995.
MLA-Zitierstil (9. Ausg.)Capper, David, et al. "Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine." International Journal of Molecular Sciences, vol. 18, no. 5, 2017, https://doi.org/10.3390/ijms18050995.